Veritas In Silico Inc. (JP:130A) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Veritas In Silico Inc. has revised its financial forecast for FY2024, anticipating a significant drop in revenue and profits due to delays in securing two new contract agreements. Despite the postponement, the company remains optimistic about future growth, with plans to pursue additional contracts and expand its joint drug discovery research. These efforts aim to enhance long-term business revenue and establish Veritas as a key player in mRNA-related drug discovery.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.